Up next

Company Executives Outline Growth Strategies and Expansions at the DCAT Member Company Announcement Forum

In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally scheduled to be held on March 23 in New York, these announcements were selected by the Announcement Oversight Task Force, as they present the latest major company news impacting the pharmaceutical manufacturing value chain. CEOs and senior executives from DCAT member companies outline their companies’ growth strategies by providing updates on key mergers and acquisitions and expansions with news from the following companies: Cambrex, Recipharm, Thermo Fisher Scientific, Lonza, SK pharmteco, Catalent, Biocon, CordenPharma, and WuXi STA. The individual news developments are outlined below.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The Making of a Molecule: Peptide Synthesis 

By
The success of the GLP-1 agonists and related follow-on drugs has renewed interest in peptide-based drugs. Industry experts share their perspectives on the latest in peptide synthesis. 

FDA Launches 1-Day Inspections Pilot

By
As part of a broader initiative to make its inspectional resources efficient, FDA has launched a pilot for one-day inspectional assessments. What does the new program involve?

Manufacturing Insights: Novartis’ Next Move

By
Novartis announced this week another leg in its $23-billion US capital investment plan—a new API manufacturing facility in North Carolina. Is the company’s manufacturing strategy aligning with its overall growth strategy?

Finding a Niche: Rare-Disease Drugs & Deal-Making

By
Are rare-disease drugs still factoring into the growth strategies of the pharmaceutical majors? Which recent deals stand out? DCAT Value Chain Insights takes an inside look at the companies, products, and deals.